534 related articles for article (PubMed ID: 34071188)
1. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.
Kalathil SG; Thanavala Y
Cells; 2021 May; 10(6):. PubMed ID: 34071188
[TBL] [Abstract][Full Text] [Related]
2. T and NK Cell-Based Immunotherapy in Chronic Viral Hepatitis and Hepatocellular Carcinoma.
Fisicaro P; Boni C
Cells; 2022 Jan; 11(2):. PubMed ID: 35053296
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
[TBL] [Abstract][Full Text] [Related]
4. The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications.
Sajid M; Liu L; Sun C
Front Immunol; 2022; 13():887186. PubMed ID: 35669776
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy.
Liu P; Chen L; Zhang H
J Immunol Res; 2018; 2018():1206737. PubMed ID: 30255103
[TBL] [Abstract][Full Text] [Related]
6. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z
Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014
[TBL] [Abstract][Full Text] [Related]
7. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
Bozward AG; Warricker F; Oo YH; Khakoo SI
Front Immunol; 2021; 12():643310. PubMed ID: 33995362
[TBL] [Abstract][Full Text] [Related]
8. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.
Sun C; Sun H; Zhang C; Tian Z
Cell Mol Immunol; 2015 May; 12(3):292-302. PubMed ID: 25308752
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.
Yu M; Li Z
Front Med; 2017 Dec; 11(4):509-521. PubMed ID: 28780700
[TBL] [Abstract][Full Text] [Related]
10. Natural Killer Cell Responses in Hepatocellular Carcinoma: Implications for Novel Immunotherapeutic Approaches.
Mantovani S; Oliviero B; Varchetta S; Mele D; Mondelli MU
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32283827
[TBL] [Abstract][Full Text] [Related]
11. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
12. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review.
Schoenberg MB; Li X; Li X; Han Y; Börner N; Koch D; Guba MO; Werner J; Bazhin AV
Int Immunopharmacol; 2021 Dec; 101(Pt A):108220. PubMed ID: 34673334
[TBL] [Abstract][Full Text] [Related]
13. RAC1
Shi X; Chen W; Yin Y; Cao H; Wang X; Jiang W; Li Q; Li X; Yu Y; Wang X
Cancer Lett; 2024 Jun; 592():216909. PubMed ID: 38679407
[TBL] [Abstract][Full Text] [Related]
14. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
15. Novel natural killer cell-mediated cancer immunotherapeutic activity of anisomycin against hepatocellular carcinoma cells.
Kim M; Lee SJ; Shin S; Park KS; Park SY; Lee CH
Sci Rep; 2018 Jul; 8(1):10668. PubMed ID: 30006566
[TBL] [Abstract][Full Text] [Related]
16. Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients.
Qian L; Wang N; Tian H; Jin H; Zhao H; Niu C; He H; Ge T; Han W; Hu J; Li D; Han F; Xu J; Ding X; Chen J; Li W; Cui J
J Immunol Res; 2016; 2016():6837241. PubMed ID: 27069936
[TBL] [Abstract][Full Text] [Related]
17. Prospects and Challenges for T Cell-Based Therapies of HCC.
Woller N; Engelskircher SA; Wirth T; Wedemeyer H
Cells; 2021 Jun; 10(7):. PubMed ID: 34209393
[TBL] [Abstract][Full Text] [Related]
18. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications.
Sung PS; Jang JW
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30463262
[TBL] [Abstract][Full Text] [Related]
19. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.
Zhang PF; Gao C; Huang XY; Lu JC; Guo XJ; Shi GM; Cai JB; Ke AW
Mol Cancer; 2020 Jun; 19(1):110. PubMed ID: 32593303
[TBL] [Abstract][Full Text] [Related]
20. STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC.
Han Q; Wang Y; Pang M; Zhang J
J Exp Clin Cancer Res; 2017 Nov; 36(1):156. PubMed ID: 29115974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]